Developing a functional precision medicine assay to predict pathological complete response in patients with triple-negative breast cancer: Interim results from the PEAR-TNBC Trial

Peter Hall, Matthew Williams, Eleonora Peerani, Elli Tham, Francesco Iori, George Richard Tiger Bevan de Fraine, Kerrie Loughrey, Andreas Dimitri Kaffa, Thomas David Laurent Richardson, Carolina Liberal, Angeliki Velentza-Almpani, Demi Annemarie Wiskerke, Farah Sangkolah, Aston Martin Crawley, Jay Kearney, Nourdine Kabirou Bah, Marios Konstantinos Tasoulis, Cliona C Kirwan, Susan Cleator, Steve Chan, Duleek Ranatunga
doi: https://doi.org/10.1101/2024.10.25.24314885

Data Availability

Data are not publicly available due to the sensitive commercial nature of the data

Back to top
Posted November 01, 2024.
Download PDF
Data/Code
Email
Developing a functional precision medicine assay to predict pathological complete response in patients with triple-negative breast cancer: Interim results from the PEAR-TNBC Trial
Peter Hall, Matthew Williams, Eleonora Peerani, Elli Tham, Francesco Iori, George Richard Tiger Bevan de Fraine, Kerrie Loughrey, Andreas Dimitri Kaffa, Thomas David Laurent Richardson, Carolina Liberal, Angeliki Velentza-Almpani, Demi Annemarie Wiskerke, Farah Sangkolah, Aston Martin Crawley, Jay Kearney, Nourdine Kabirou Bah, Marios Konstantinos Tasoulis, Cliona C Kirwan, Susan Cleator, Steve Chan, Duleek Ranatunga
medRxiv 2024.10.25.24314885; doi: https://doi.org/10.1101/2024.10.25.24314885
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area